N/A Completed N=2,016

Xeljanz Special Investigation for Long-term Use in UC Patients

Ulcerative Colitis

Source: ClinicalTrials.gov NCT03643211 ↗

Enrolled (actual)

2,016

Serious AEs

5.2%

Results posted

Oct 2024

Primary outcomePrimary: Number of Participants With Adverse Drug Reactions — 466; 46 Participants

Summary

Secondary data collection study: safety and effectiveness of Xeljanz in UC patients under Japanese medical practice

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Adverse Drug Reactions	466; 46	—

Eligibility Criteria

Inclusion Criteria

Patients with ulcerative colitis treated with XELJANZ
Patients naive to XELJANZ in the treatment of ulcerative colitis

Exclusion Criteria

None

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03643211). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.